Logo image of BIOX

BIOCERES CROP SOLUTIONS CORP (BIOX) Stock Fundamental Analysis

NASDAQ:BIOX - Nasdaq - KYG1117K1141 - Common Stock - Currency: USD

3.37  -0.22 (-6.13%)

After market: 3.37 0 (0%)

Fundamental Rating

3

We assign a fundamental rating of 3 out of 10 to BIOX. BIOX was compared to 85 industry peers in the Chemicals industry. Both the profitability and financial health of BIOX have multiple concerns. BIOX has a decent growth rate and is not valued too expensively.


Dividend Valuation Growth Profitability Health

Quickly go to:

2

1. Profitability

1.1 Basic Checks

BIOX had negative earnings in the past year.
BIOX had a positive operating cash flow in the past year.
The reported net income has been mixed in the past 5 years: BIOX reported negative net income in multiple years.
The reported operating cash flow has been mixed in the past 5 years: BIOX reported negative operating cash flow in multiple years.
BIOX Yearly Net Income VS EBIT VS OCF VS FCFBIOX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20M -20M 40M

1.2 Ratios

BIOX has a Return On Assets of -1.13%. This is in the lower half of the industry: BIOX underperforms 62.35% of its industry peers.
BIOX has a Return On Equity (-2.94%) which is in line with its industry peers.
BIOX has a worse Return On Invested Capital (2.92%) than 62.35% of its industry peers.
Measured over the past 3 years, the Average Return On Invested Capital for BIOX is in line with the industry average of 6.67%.
Industry RankSector Rank
ROA -1.13%
ROE -2.94%
ROIC 2.92%
ROA(3y)0.43%
ROA(5y)0.14%
ROE(3y)0.56%
ROE(5y)-0.23%
ROIC(3y)6.06%
ROIC(5y)8.13%
BIOX Yearly ROA, ROE, ROICBIOX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -20 -40 -60 -80

1.3 Margins

Looking at the Operating Margin, with a value of 5.69%, BIOX is doing worse than 64.71% of the companies in the same industry.
BIOX's Operating Margin has declined in the last couple of years.
Looking at the Gross Margin, with a value of 39.83%, BIOX belongs to the top of the industry, outperforming 83.53% of the companies in the same industry.
In the last couple of years the Gross Margin of BIOX has declined.
Industry RankSector Rank
OM 5.69%
PM (TTM) N/A
GM 39.83%
OM growth 3Y-17.81%
OM growth 5Y-13.52%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-1.98%
GM growth 5Y-2.6%
BIOX Yearly Profit, Operating, Gross MarginsBIOX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20 40

More info and screens

3

2. Health

2.1 Basic Checks

The Return on Invested Capital (ROIC) is below the Cost of Capital (WACC), so BIOX is destroying value.
Compared to 1 year ago, BIOX has about the same amount of shares outstanding.
The number of shares outstanding for BIOX has been increased compared to 5 years ago.
Compared to 1 year ago, BIOX has a worse debt to assets ratio.
BIOX Yearly Shares OutstandingBIOX Yearly Shares OutstandingYearly Shares Outstanding 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M
BIOX Yearly Total Debt VS Total AssetsBIOX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M 800M

2.2 Solvency

The Debt to FCF ratio of BIOX is 9.52, which is on the high side as it means it would take BIOX, 9.52 years of fcf income to pay off all of its debts.
BIOX has a better Debt to FCF ratio (9.52) than 63.53% of its industry peers.
A Debt/Equity ratio of 0.28 indicates that BIOX is not too dependend on debt financing.
BIOX's Debt to Equity ratio of 0.28 is fine compared to the rest of the industry. BIOX outperforms 75.29% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.28
Debt/FCF 9.52
Altman-Z N/A
ROIC/WACC0.33
WACC8.75%
BIOX Yearly LT Debt VS Equity VS FCFBIOX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 100M 200M 300M

2.3 Liquidity

BIOX has a Current Ratio of 1.02. This is a normal value and indicates that BIOX is financially healthy and should not expect problems in meeting its short term obligations.
Looking at the Current ratio, with a value of 1.02, BIOX is doing worse than 88.24% of the companies in the same industry.
BIOX has a Quick Ratio of 1.02. This is a bad value and indicates that BIOX is not financially healthy enough and could expect problems in meeting its short term obligations.
BIOX has a worse Quick ratio (0.74) than 81.18% of its industry peers.
Industry RankSector Rank
Current Ratio 1.02
Quick Ratio 0.74
BIOX Yearly Current Assets VS Current LiabilitesBIOX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M 400M

More info and screens

4

3. Growth

3.1 Past

The earnings per share for BIOX have decreased strongly by -551.72% in the last year.
BIOX shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -13.69%.
The Revenue has been growing by 23.73% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)-551.72%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-114.29%
Revenue 1Y (TTM)-13.69%
Revenue growth 3Y31.01%
Revenue growth 5Y23.73%
Sales Q2Q%-27.86%

3.2 Future

Based on estimates for the next years, BIOX will show a very strong growth in Earnings Per Share. The EPS will grow by 69.95% on average per year.
The Revenue is expected to grow by 4.00% on average over the next years.
EPS Next Y-212.37%
EPS Next 2Y88.26%
EPS Next 3Y92.09%
EPS Next 5Y69.95%
Revenue Next Year-21.79%
Revenue Next 2Y-8.39%
Revenue Next 3Y-0.58%
Revenue Next 5Y4%

3.3 Evolution

The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
BIOX Yearly Revenue VS EstimatesBIOX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 200M 400M 600M
BIOX Yearly EPS VS EstimatesBIOX Yearly EPS VS EstimatesYearly EPS VS Estimates 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 0.2 -0.2 0.4 0.6 0.8 1

More info and screens

4

4. Valuation

4.1 Price/Earnings Ratio

BIOX reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
BIOX is valuated correctly with a Price/Forward Earnings ratio of 16.12.
The rest of the industry has a similar Price/Forward Earnings ratio as BIOX.
The average S&P500 Price/Forward Earnings ratio is at 36.36. BIOX is valued rather cheaply when compared to this.
Industry RankSector Rank
PE N/A
Fwd PE 16.12
BIOX Price Earnings VS Forward Price EarningsBIOX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 -20

4.2 Price Multiples

The rest of the industry has a similar Enterprise Value to EBITDA ratio as BIOX.
Based on the Price/Free Cash Flow ratio, BIOX is valued cheaper than 91.76% of the companies in the same industry.
Industry RankSector Rank
P/FCF 7.36
EV/EBITDA 10.02
BIOX Per share dataBIOX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 4 6

4.3 Compensation for Growth

BIOX's earnings are expected to grow with 92.09% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y88.26%
EPS Next 3Y92.09%

More info and screens

0

5. Dividend

5.1 Amount

BIOX does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

BIOCERES CROP SOLUTIONS CORP

NASDAQ:BIOX (8/6/2025, 8:10:29 PM)

After market: 3.37 0 (0%)

3.37

-0.22 (-6.13%)

Chartmill FA Rating
GICS SectorMaterials
GICS IndustryGroupMaterials
GICS IndustryChemicals
Earnings (Last)05-21 2025-05-21/bmo
Earnings (Next)N/A N/A
Inst Owners22.54%
Inst Owner Change-0.36%
Ins Owners1.33%
Ins Owner ChangeN/A
Market Cap211.33M
Analysts84
Price Target7.52 (123.15%)
Short Float %1.28%
Short Ratio3.83
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly Dividend0
Dividend Growth(5Y)N/A
DP0%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-1.45%
Min EPS beat(2)-89.82%
Max EPS beat(2)86.93%
EPS beat(4)1
Avg EPS beat(4)-297.85%
Min EPS beat(4)-1076.47%
Max EPS beat(4)86.93%
EPS beat(8)1
Avg EPS beat(8)-217.21%
EPS beat(12)2
Avg EPS beat(12)-43.03%
EPS beat(16)3
Avg EPS beat(16)-46.14%
Revenue beat(2)0
Avg Revenue beat(2)-13.11%
Min Revenue beat(2)-19.15%
Max Revenue beat(2)-7.07%
Revenue beat(4)0
Avg Revenue beat(4)-13.33%
Min Revenue beat(4)-19.15%
Max Revenue beat(4)-7.07%
Revenue beat(8)1
Avg Revenue beat(8)-8.07%
Revenue beat(12)4
Avg Revenue beat(12)-0.28%
Revenue beat(16)8
Avg Revenue beat(16)9.32%
PT rev (1m)-3.28%
PT rev (3m)-3.28%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-37.5%
EPS NY rev (1m)0%
EPS NY rev (3m)39.06%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-5.84%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-2.7%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE 16.12
P/S 0.55
P/FCF 7.36
P/OCF 4.48
P/B 0.69
P/tB 14.61
EV/EBITDA 10.02
EPS(TTM)-0.13
EYN/A
EPS(NY)0.21
Fwd EY6.2%
FCF(TTM)0.46
FCFY13.59%
OCF(TTM)0.75
OCFY22.31%
SpS6.11
BVpS4.92
TBVpS0.23
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -1.13%
ROE -2.94%
ROCE 4.68%
ROIC 2.92%
ROICexc 3.19%
ROICexgc 10.26%
OM 5.69%
PM (TTM) N/A
GM 39.83%
FCFM 7.49%
ROA(3y)0.43%
ROA(5y)0.14%
ROE(3y)0.56%
ROE(5y)-0.23%
ROIC(3y)6.06%
ROIC(5y)8.13%
ROICexc(3y)6.87%
ROICexc(5y)10.39%
ROICexgc(3y)15.77%
ROICexgc(5y)22.76%
ROCE(3y)9.78%
ROCE(5y)13.22%
ROICexcg growth 3Y-15.22%
ROICexcg growth 5Y-15.76%
ROICexc growth 3Y-21.1%
ROICexc growth 5Y-17.96%
OM growth 3Y-17.81%
OM growth 5Y-13.52%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-1.98%
GM growth 5Y-2.6%
F-Score4
Asset Turnover0.48
Health
Industry RankSector Rank
Debt/Equity 0.28
Debt/FCF 9.52
Debt/EBITDA 1.89
Cap/Depr 77.16%
Cap/Sales 4.81%
Interest Coverage 0.88
Cash Conversion 103.14%
Profit Quality N/A
Current Ratio 1.02
Quick Ratio 0.74
Altman-Z N/A
F-Score4
WACC8.75%
ROIC/WACC0.33
Cap/Depr(3y)107.09%
Cap/Depr(5y)127.69%
Cap/Sales(3y)4.36%
Cap/Sales(5y)4.48%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-551.72%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-114.29%
EPS Next Y-212.37%
EPS Next 2Y88.26%
EPS Next 3Y92.09%
EPS Next 5Y69.95%
Revenue 1Y (TTM)-13.69%
Revenue growth 3Y31.01%
Revenue growth 5Y23.73%
Sales Q2Q%-27.86%
Revenue Next Year-21.79%
Revenue Next 2Y-8.39%
Revenue Next 3Y-0.58%
Revenue Next 5Y4%
EBIT growth 1Y-42.48%
EBIT growth 3Y7.68%
EBIT growth 5Y7%
EBIT Next Year-14.14%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y332.69%
FCF growth 3YN/A
FCF growth 5Y-6.35%
OCF growth 1Y734.34%
OCF growth 3YN/A
OCF growth 5Y7.02%